TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Taysha Gene Therapies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.94+0.32 (+8.84%)
Close on Oct 19, 2026
- Market cap
- $1.45B
- P/E (TTM)
- –
- Dividend yield
- –
Taysha Gene Therapies statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Market Cap | $1.28B | $166.30M |
| Enterprise Value | $877.64M | $87.12M |
| PS Ratio | 234.05 | 3.60 |
| PB Ratio | 3.31 | 2.03 |
| P/TBV Ratio | 3.31 | 2.31 |
Enterprise value
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| EV / Sales | 160.01 | 2.43 |
Income (trailing twelve months)
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Revenue | $5.49M | $57.94M |
| Operating Income | -$153.16M | -$21.49M |
| Net Income | -$149.63M | -$22.46M |
| EBITDA | -$153.16M | -$17.14M |
| EPS (Diluted) | -$0.42 | -$0.83 |
Margins
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Operating Margin | -2792.3% | -44.5% |
| Profit Margin | -2728.0% | -39.2% |
| EBITDA Margin | -2792.3% | -31.3% |
| FCF Margin | -2417.0% | -8.85% |
Returns
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Return on Equity (ROE) | -47.1% | -53.2% |
| Return on Assets (ROA) | -37.2% | -41.0% |
| Return on Capital Employed (ROCE) | -34.5% | -38.0% |
Growth
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -32.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 57.5% | 2.25% |
Balance sheet
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $455.41M | $62.64M |
| Total Debt | $49.26M | $120.13M |
| Net Cash (Debt) | $406.15M | $15.77M |
| Net Cash Per Share | $1.25 | $0.66 |
| Equity (Book Value) | $387.27M | $48.61M |
| Book Value Per Share | $1.19 | $1.36 |
| Tangible Book Value | $387.27M | $23.01M |
| Working Capital | $435.46M | $75.09M |
Financial position
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Current Ratio | 17.76 | 3.30 |
| Quick Ratio | 17.53 | 2.39 |
| Debt / Equity | 0.13 | 0.51 |
| Interest Coverage | -3646.64 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Operating Cash Flow | -$132.19M | -$12.39M |
| Capital Expenditures | -$381.00K | -$1.07M |
| Free Cash Flow | -$132.57M | -$20.34M |
| FCF Per Share | -$0.41 | -$0.42 |
Efficiency
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $55.40K | $398.96K |
| Profits Per Employee | -$1.51M | -$705.27K |
| Employee Count | 99 | 74 |
Dividends and yields
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Earnings Yield | -11.7% | -22.8% |
| FCF Yield | -10.3% | -9.02% |
Shares
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Shares Outstanding | 325,834,000 | 58,139,000 |
| Shares Change (YoY) | 31.1% | 11.1% |
| Shares Change (QoQ) | 13.2% | 0.54% |
| Float | 290,854,000 | 49,154,900 |
| Shares Held by Insiders | 10.7% | 11.6% |
| Shares Held by Institutions | 91.9% | 59.4% |
Taxes
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Income Tax | $0 | $89.00K |
Scores
| Measure | Taysha Gene Therapies | Industry median |
|---|---|---|
| Altman Z-Score | 6.93 | -0.27 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Taysha Gene Therapies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.